HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

ABT 281

ascomycin analog; structure in first source

Also Known As:

ABT-281

Networked: 2 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amides: 2428
  - Lactams: 2198
    - ABT 281: 2
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Lactams: 2198
    - ABT 281: 2

Related Diseases

1.	Skin Diseases (Skin Disease) 10/01/1998 - "The potent topical activity and reduced systemic exposure of ABT-281 may thus provide both efficacy and a greater margin of safety for topical therapy of skin diseases." 05/01/1999 - "The macrolactam ascomycin analog, ABT-281, was found to inhibit potently T cell function across species and to inhibit expression of multiple cytokines in human peripheral blood leukocytes which have been found in human skin disease cells and tissues. " 05/01/1999 - "The potent topical activity of ABT-281 in swine, its superior efficacy, its rapid systemic clearance following uptake into the bloodstream, and its ability to inhibit cytokine biosynthesis of both Th1 and Th2 cell subsets, suggests that it will have a broad therapeutic value in inflammatory skin diseases, including psoriasis, atopic dermatitis, and allergic contact dermatitis."
2.	Allergic Contact Dermatitis 05/01/1999 - "The potent topical activity of ABT-281 in swine, its superior efficacy, its rapid systemic clearance following uptake into the bloodstream, and its ability to inhibit cytokine biosynthesis of both Th1 and Th2 cell subsets, suggests that it will have a broad therapeutic value in inflammatory skin diseases, including psoriasis, atopic dermatitis, and allergic contact dermatitis."
3.	Psoriasis (Pustulosis Palmaris et Plantaris) 05/01/1999 - "The potent topical activity of ABT-281 in swine, its superior efficacy, its rapid systemic clearance following uptake into the bloodstream, and its ability to inhibit cytokine biosynthesis of both Th1 and Th2 cell subsets, suggests that it will have a broad therapeutic value in inflammatory skin diseases, including psoriasis, atopic dermatitis, and allergic contact dermatitis."
4.	Atopic Dermatitis (Atopic Eczema) 05/01/1999 - "The potent topical activity of ABT-281 in swine, its superior efficacy, its rapid systemic clearance following uptake into the bloodstream, and its ability to inhibit cytokine biosynthesis of both Th1 and Th2 cell subsets, suggests that it will have a broad therapeutic value in inflammatory skin diseases, including psoriasis, atopic dermatitis, and allergic contact dermatitis."
5.	Contact Dermatitis (Eczema, Contact) 10/01/1998 - "administration in the swine contact hypersensitivity model, ABT-281 was 19- and 61-fold less potent, respectively, than FK506. " 05/01/1999 - "ABT-281 was shown to have potent topical activity (ED50 = 0.6% in acetone/olive oil) in a stringent swine model of allergic contact hypersensitivity, but its potency was markedly reduced compared with ascomycin when administered systemically due to more rapid clearance. " 05/01/1999 - "Compared with a wide potency range of topical corticosteroids in clinical formulations, 0.3% and 1% ABT-281 ointments profoundly inhibited dinitrochlorobenzene-induced contact hypersensitivity in the pig by 78% and 90%, respectively, whereas super-potent steroids such as clobetasol propionate only inhibited in the 50% range and mild to moderate potency steroids such as fluocinolone acetonide were inactive. "

Related Drugs and Biologics

1.	Cytokines
2.	Tacrolimus (Prograf)
3.	Steroids
4.	Ointments (Pastes)
5.	Fluocinolone Acetonide (Capex)
6.	Dinitrochlorobenzene (DNCB)
7.	Clobetasol (Clobetasol Propionate)
8.	Adrenal Cortex Hormones (Corticosteroids)
9.	Acetone
10.	Olive Oil

Related Therapies and Procedures

1.	Therapeutics